23.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$23.22
Aprire:
$23.17
Volume 24 ore:
969.95K
Relative Volume:
1.00
Capitalizzazione di mercato:
$1.55B
Reddito:
$9.98M
Utile/perdita netta:
$-154.08M
Rapporto P/E:
-9.0504
EPS:
-2.58
Flusso di cassa netto:
$-159.66M
1 W Prestazione:
+4.19%
1M Prestazione:
+8.81%
6M Prestazione:
-2.79%
1 anno Prestazione:
-46.76%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Confronta CLDX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CLDX
Celldex Therapeutics Inc
|
23.35 | 1.54B | 9.98M | -154.08M | -159.66M | -2.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-28 | Iniziato | Canaccord Genuity | Buy |
2025-03-20 | Iniziato | Morgan Stanley | Overweight |
2025-02-13 | Iniziato | UBS | Buy |
2024-10-07 | Iniziato | Citigroup | Buy |
2024-09-30 | Iniziato | Goldman | Neutral |
2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2024-06-18 | Iniziato | Stifel | Buy |
2024-06-11 | Iniziato | Wolfe Research | Outperform |
2023-12-20 | Iniziato | TD Cowen | Outperform |
2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2023-08-22 | Iniziato | Wells Fargo | Underweight |
2021-09-17 | Iniziato | Jefferies | Buy |
2021-09-10 | Iniziato | SVB Leerink | Outperform |
2021-07-22 | Iniziato | Guggenheim | Buy |
2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
2017-08-01 | Ripresa | H.C. Wainwright | Buy |
2016-11-07 | Iniziato | Aegis Capital | Buy |
2016-03-08 | Downgrade | Jefferies | Buy → Hold |
2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
2016-03-01 | Iniziato | H.C. Wainwright | Buy |
2015-08-11 | Reiterato | Brean Capital | Buy |
2015-08-11 | Reiterato | Oppenheimer | Outperform |
2015-08-11 | Reiterato | ROTH Capital | Buy |
2015-06-02 | Reiterato | WBB Securities | Strong Buy |
2014-11-17 | Reiterato | ROTH Capital | Buy |
2014-03-04 | Reiterato | Oppenheimer | Outperform |
2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
2013-02-26 | Reiterato | Oppenheimer | Outperform |
2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
2012-10-02 | Reiterato | Oppenheimer | Outperform |
2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Why Celldex Therapeutics Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Metal.it
Celldex Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What drives Celldex Therapeutics Inc. stock priceFree Investment Risk Control - PrintWeekIndia
What analysts say about Celldex Therapeutics Inc. stockConsistently superior profits - Autocar Professional
Is Celldex Therapeutics Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com
Is Celldex Therapeutics Inc. stock a good hedge against inflationFree Short-Term Stock Picks - Newser
What makes Celldex Therapeutics Inc. stock price move sharplySafety First Trading Signals - Newser
How Celldex Therapeutics Inc. stock performs during market volatility2x Return Forecast - beatles.ru
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, - openPR.com
Cholera Vaccines Market Deep Research and Growth in Future Scope - openPR.com
Is Celldex Therapeutics, Inc. technically bullish or bearish? - MarketsMojo
(06/24/25) CLDX: A Promising Biotech Name Targeting CSU - moneyshow.com
Chronic spontaneous urticaria improvements persist 28 weeks after barzolvolimab stopped - Healio
Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada
Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):